TNF and Alzheimer disease: We, and others have shown that serum TNF-α levels are increased in people with AD, which contributes to faster disease progression and inhibition using the TNF-α inhibitor, etanercept, showed a trend toward a slower rate of decline (Holmes et al., 2009, 2011; Butchart et al., 2015).